Project Grant R21CA303350
Award Date 9/8/25
Completion Date 8/31/27
Dollars Obligated $359K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $1,812,356.00 to The University of Texas MD Anderson Cancer Center (MD Anderson) to develop a rapid, inexpensive microfluidics-based approach for dose-on-demand production of human dosage quantities of ready-to-inject radiopharmaceuticals. The project aims to...
- This federal Project Grant award in the amount of $449,625.00 was issued on September 15, 2025 by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The award supports the development of statistical methods to quantify heterogeneous cell-cell interaction patterns in spatial transcriptomics data across various human diseases, including pancreatic cancer, gastric cancer, and Alzheimer's disease. The key products...
- This Project Grant award from the National Cancer Institute's (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund a research project titled "Innovative Scan Protocols with Combined Long Axial FOV PET and Spectral CT for Improved Quantification in Oncology". The $666,670 award, effective January 15, 2025, aims to develop advanced imaging protocols and processing techniques that utilize both positron emission tomography (PET) and spectral computed tomography (CT) to enhance...
- This federal Project Grant award of $163,500.00 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to develop new therapies for diffuse-type gastric cancer (DGAC). The primary awardee, The University of Texas MD Anderson Cancer Center, aims to unravel the mechanisms of DGAC tumorigenesis and apply that knowledge to lay a foundation for DGAC therapy development. Key objectives include determining the impact of drug candidates on DGAC stemness,...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $760,982 to The University of Texas MD Anderson Cancer Center to investigate the role of the GFPT2 enzyme in radiation-induced cardiovascular disease. The project aims to determine the fundamental mechanisms contributing to radiation-induced cardiovascular disease, identify high-risk patients, and establish new treatment approaches. Key objectives...
- This $149,394 Project Grant was awarded on August 1, 2025 by the National Cancer Institute (NCI), part of the Department of Health and Human Services, under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The grant supports research led by the University of California, Davis to advance the development of targeted radiopharmaceuticals for cancer diagnosis and therapy. Specifically, the research focuses on designing, synthesizing, and optimizing novel molecular imaging...
- This $150,104 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to understand the evolutionary trajectories of complex genomic rearrangements in cancer. The project aims to develop novel computational approaches, "AGAVE" and "ROSE", to characterize the timing and dynamics of focal amplifications and structural variants during tumor evolution. The research will map these evolutionary patterns across...
- The University of Texas MD Anderson Cancer Center received a $2,457,127 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to support the "INHANCE: Imaging Innovation for Head and Neck Cancer Evaluation & Treatment Delivery" research project. The goal of this 5-year project, starting August 18, 2025, is to leverage advanced imaging and computational analysis to better predict, detect, prevent, and manage normal tissue injury in head and...
- The federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $400,000.00 in funding to Zeest Bio Inc. to develop a novel liver-specific positron emission tomography (PET) tracer. The project aims to complete the preclinical testing and Investigational New Drug (IND)-enabling studies required for first-in-human clinical trials of this PET tracer. This tracer is hypothesized to offer higher sensitivity for detecting smaller...
- The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...